United States
Creative Biostructure stands as a key player in the realms of biotechnology and pharmaceutical innovation, delivering specialized services in structural biology and membrane protein technologies. They are at the forefront of developing structure-based therapies, leveraging their proprietary gene-to-structure pipelines. Their comprehensive approach allows for effective determination and analysis of challenging macromolecules, including GPCRs, ion channels, and other critical proteins.
Though the company’s founding date remains undisclosed, Creative Biostructure is headquartered in the United States and serves both academic institutions and industry players. Their unique Membrane Protein Screening Platform enhances their service offering, ensuring access to cutting-edge techniques with competitive pricing and expedited turnaround times.
With no reported external funding or investments to date, Creative Biostructure presents a potential untapped opportunity for investors seeking involvement in the biotech and pharmaceutical sectors. Their advanced technological capabilities and diverse service portfolio position them as a promising candidate for strategic investment, aiming for depth in the structural biology domain.
